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Additives for vaccine storage to improve thermal
stability of adenoviruses from hours to months
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Up to 80% of the cost of vaccination programmes is due to the cold chain problem (that is,
keeping vaccines cold). Inexpensive, biocompatible additives to slow down the degradation of
virus particles would address the problem. Here we propose and characterize additives that,
already at very low concentrations, improve the storage time of adenovirus type 5. Anionic
gold nanoparticles (108–10 6M) or polyethylene glycol (PEG, molecular weight
B8,000Da, 10 7–104M) increase the half-life of a green ﬂuorescent protein expressing
adenovirus fromB48 h to 21 days at 37 C (from 7 to430 days at room temperature). They
replicate the known stabilizing effect of sucrose, but at several orders of magnitude lower
concentrations. PEG and sucrose maintained immunogenicity in vivo for viruses stored for 10
days at 37 C. To achieve rational design of viral-vaccine stabilizers, our approach is aided by
simpliﬁed quantitative models based on a single rate-limiting step.
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V
accination saves millions of lives every year. Attenuated,
genetically modiﬁed or inactivated viruses are still the key
active ingredients of many vaccines, despite recent
progress in the use of virus-like particles or proteins in vaccine
preparations. Maintaining the potency of these viral particles
against degradation is a major challenge in providing proper
immunization services. Typically, this requires keeping vaccines
refrigerated at all times from production to administration—a
major undertaking especially in remote regions of developing
countries. Termed the cold chain problem, the high cost and risk
associated with protecting vaccines from deterioration has been
identiﬁed by the World Health Organization as one of the most
important challenges for the extension of global vaccination
programmes1. The development of thermally stable formulations
for the major vaccines could relieve bottlenecks in the vaccine
supply chain2. The addition of additives to existing vaccines
usually means to get again through the costly process of approval
by health authorities, which is commercially unattractive3.
Therefore, proposing solutions that use inexpensive additives for
stabilization increases the likelihood of their adoption by vaccine
manufacturers in the development of new vaccines
There are two temperature-induced risk factors for vaccines,
aluminium salt aggregation due to freezing (aluminium is a salt
adjuvant that serves as an immune booster)4 and inactivation of
the attenuated or inactivated virus by exposure to elevated
temperatures2. While the ﬁrst risk is dealt with stabilizers such as
anti-freezing agents5,6, sucrose (in liquid vaccine preparation at
millimolar concentration or in solid vaccines in milligram
quantities) being the most common7, the reasons for the
second one are largely unknown and hence only empirical
solutions are available. Few successful approaches to stabilize viral
vaccines have been proposed4. One strategy is the freeze-dried
preparation of vaccines, such as hepatitis B, rotavirus, measles,
mumps and rubella virus vaccines8. Another approach is to
immobilize viral particles in a sugar glass on a ﬁlter9. Solid
preparations are known to drastically improve the stability at
elevated temperatures. One approach that has been in
development in recent years is the addition of sucrose at molar
concentrations to vaccine formulations4,5,9–12. Another approach
uses silk ﬁbres. These silk ﬁbres stabilize the vaccine during
transport and storage in its powder form as well as the
reconstituted vaccine13.
Earlier empirical approaches stabilize liquid formulations of
Ad5 viral vaccines were described by Evan et al.10. They identiﬁed
freeze-thaw damage, surface adsorption and free radical oxidation
as reasons of virus destruction. They tested a combination of
buffering molecules, ions and sucrose and found a solution
containing 5w/v% sucrose as the most effective cryoprotectant.
Other compounds were polysorbate-80 as non-ionic surfactant,
metal-ion catalyzed free-radical oxidation inhibitor, the
free-radical oxidation inhibitors, ethanol and histidine, and the
metal-ion chelator ethylenediaminetetraacetic acid preserving
99% infectivity for Ad5 viruses stored for 24 months at 4 C,
and 95% for 1 day at 37 C. Stewart et al.12 showed that a
preservation of infectivity of adenovirus for a sucrose-stabilized
liquid formulation for up to 6 weeks at 40 C, hence conﬁrming
the stabilizing effect of sucrose.
Here we propose and evaluate a diverse set of additives to
stabilize exemplarily adenoviral vaccines at ambient tempera-
tures. Using in vitro and in vivo measurements of adenoviral
infectivity over time, we demonstrate how vastly different
media—simple sugars, long-chain polymers and coated nano-
particles (NPs), with concentrations spanning many orders of
magnitude—can be used to enhance the lifetime of viral
formulations from several days to weeks or months. We interpret
these experimental results in the context of a model of adenoviral
capsid degradation that compares the effects of different physical
processes that may inﬂuence virus lifetimes.
Results
Maintenance of adenoviral infectivity in vitro. Our additives are
tested on genetically modiﬁed adenovirus serotype 5 (Ad5).
Adenovirus (Ad) is one of the most intensely investigated viral
particles for genetically engineered chimeric vaccines. Ad chi-
meric vaccines14 for highly pathogenic viruses are in different
stages of development: rabies15 is commercially available (for fox
and skunk vaccination: ONRAB), Ebola16, human
immunodeﬁciency virus14 and H5N1 avian ﬂu17,18 are under
development. The virus itself is chosen as a good vehicle because
even if it is still infective, it only causes mild self-limiting
respiratory syndrome in immune competent individuals.
Genetically engineered Ad is especially vulnerable to the
stability problem stated above19,20. For example, it was found
that deletion of two gene regions (E1 or E1/3) and replacement by
shorter or longer pieces of foreign genes leads to variations in the
thermal stability of Ad5 (ref. 21).
To address the problem of Ad stability (and for viruses in general)
we chose to work with a genetically modiﬁed replication-deﬁcient
Ad5 with deleted E1/E3 gene region replaced by an inserted green
ﬂuorescent protein (GFP) reporter gene (Ad-GFP). However, while
the Ad vector expressing GFP was ideal for optimizing stability
protocols using in vitro assays and facilitating the read-out of
infection, Ad-GFP is not a vaccine. Therefore, we utilized in vivo an
Ad expressing Chikungunya (CHIKV) non-structural protein 1
(NSP1) for a proof-of-concept experiment, to show that our
additives do not interfere with the ability of Ad to elicit immunity.
The degradation of Ad5 virions in a given storage medium was
evaluated experimentally by measuring the infectivity of the virus
preparation over time at two storage temperatures, room
temperature at 25 C (RT) and 37 C. Infectivity was measured
by the expression of the reporter gene GFP, evaluated by
ﬂuorescence-activated cells sorting, and quantiﬁed as percentage
of cells infected. We ﬁrst established the baseline stability of Ad5
by measuring its infectivity in the standard storage medium of
phosphate-buffered saline (PBS) over 21 days at the two storage
temperatures. The results are shown in Fig. 1a (symbols).
The infectivity drops to below 20% over the span of a few days;
the loss of infectivity is faster at 37 C than at RT, consistent with
loss of infectivity due to thermal degradation of virus particles.
The fact that Ad5 viruses are prone to thermally induced
changes11 was observed in our dynamic light scattering (DLS)
measurements, where an increase in hydrodynamic diameter with
increasing temperature was determined (Supplementary Fig. 1
(grey line)). The reasons for the change in hydrodynamic
diameter can be due to changes of proteins or the capsid and
hence a change in the ions and water shell around the capsid.
A direct measurement of the ﬂuctuation are too small and too fast
to be observed in DLS and in general by other existing techniques.
The simplest model for loss of infectivity assumes that
individual virus particles, or virions, degrade from a viable to a
disrupted state at a constant rate. This implies an exponential
decay in the population n(t) of infectious virions in a ﬁxed
volume of preparation: n(t)¼ n0e t/t, where n0 is the initial
population and t is the inverse decay rate, equivalent to the mean
lifetime of an individual virion. If Nc cells are inoculated by this
preparation, the absorption of viral particles by cells follows a
Poisson distribution. The fraction of cells infected equals the
probability that a cell absorbs at least one infectious particle:
Fraction of cells infected ¼ 1 exp  n tð Þ
Nc
 
¼1 exp m0e t=t
h i
ð1Þ
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where m0 is the initial ratio of infectious virions to cells. Whereas
m0 is set by the details of the infectivity assay, the lifetime t
completely quantiﬁes the loss of viable virions over time.
To test the hypothesis of constant-rate degradation, we
performed ﬁts of the infectivity data to equation (1) with m0
and t as free parameters (Fig. 1a, solid lines). The model
successfully captures the infectivity trend, which is consistent
with a constant decay rate of infective virions (quality-of-ﬁt
statistics are provided in the Supplementary Discussion). The
lifetime t is found to be around 3 days at RT and 1 day at 37 C in
PBS. These lifetime estimates provide the baseline against which
the efﬁcacy of the proposed lifetime-prolonging additives is
measured.
Exponential decay of virions at a constant rate is characteristic
of a single-step degradation reaction. The lifetime (inverse decay
rate) for such a reaction takes on the Arrhenius form22
t¼t0eDE=kBT ; ð2Þ
where t0 is a relaxation time or inverse attempt frequency
characterizing the dynamics of the degradation mechanism, DE is
the energy barrier separating the infectious from the degraded
state, kB is the Boltzmann constant and T is the temperature. The
baseline values of the relaxation time and energy barrier in PBS
can be estimated from the measured lifetimes at two different
temperatures (Fig. 1a). Assuming that DE and t0 are unchanged,
the observed change in lifetime with temperature corresponds
to an activation energy of DEE1 10 19 J, consistent with
previously reported activation energies for the degradation of phage
viruses23. The corresponding relaxation time is t0E6 10 7 s.
While equation (2) is completely general for single-step
reactions, predicting the effect of storage media on the crucial
parameters t0 and DE requires a mechanistic model for virus
degradation. A detailed analysis of all the stochastic processes that
might lead to loss of infectivity of the Ad5, taking into account its
complex structure, is beyond the scope of this work. However,
our observation that loss of infectivity is consistent with single-
step activation simpliﬁes the search for degradation models, since
the degradation rate is primarily determined by a single physical
process. In the Supplementary Discussion section, we present a
model that assumes that adenovirus degradation occurs due to
spontaneous mechanical rupture of the capsid.
To test the adequacy of the infectivity assay and the ﬁtting
procedure, we studied the thermal stability of Ad5 solutions in
the presence of sucrose, a known effective additive for viral
vaccine stabilization (for example, JE-Vax, MMR-II, Pentacel
DTaPþ IPVþHib, Rotarix, Varivax and Zostavax)7. The results
for Ad5 virus stability as a function of sucrose concentration for
the ﬁrst 75 days of the experiment are shown in Fig. 1b–d. At RT,
the virus lifetime in 0.3M sucrose solution is 30-fold higher than
that in PBS. Lifetime estimates at higher concentrations proved
unreliable because the measured fall in infectivity after 75 days
was o20% for the chosen assay. At 37 C, an 8-fold extension of
the lifetime relative to PBS is obtained in 0.6M sucrose, but the
effect saturates at higher concentrations.
These observations conﬁrm earlier ﬁndings by other
researchers that observed an increased stability for either Ad5
viruses or other viruses at higher sucrose concentration4,11,24–26.
In the Supplementary Information, we show that sucrose was also
able to stabilize herpes simplex virus-2, another example of
double-stranded DNA virus (Supplementary Fig. 1A,B) or
vesicular stomatitis virus (VSV), a RNA virus (Supplementary
Fig. 1C). The effect on VSV is not signiﬁcant for the stabilization
as the RNA virus per se is more stable in contrast to the
double-stranded DNA viruses.
The effect of sugars as stabilizers against protein unfolding is
known5,25–29. Because of this effect sucrose has been used as
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Figure 1 | Maintained Ad5 infectivity versus time in PBS and sucrose. (a) Fraction of cells infected versus storage time (days) of Ad5 in PBS at RT (blue)
and at 37 C (red). The curves are ﬁts to the expected infectivity given an exponential decay of viable Ad5 particles with characteristic lifetime t,
equation (1). (b,c) Fraction of cells infected versus storage time in different sucrose concentrations ranging from 0.14 to 1.7M at RT (b) and at 37 C (c).
(d) The lifetime of Ad5 virus as extracted from the ﬁts at 37 C (main panel) and at RT (inset). (A comparison with the infectivity change for herpes
simplex virus-2, another example of double-stranded DNA viruses, can be found in Supplementary Fig. 1.) The experiments were performed in duplicate.
Error bars represent the s.d. d, days.
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cryo-stabilizer for freeze-dried vaccines. Yet, it has been shown
that sucrose-induced stabilization of the viral capsid proteins
alone does not necessarily lead to virus capsid stabilization25.
More importantly, the protein stabilization effect is broadly
observed with many sugars9,24,30,31, but only sucrose and
trehalose seem to be effective in stabilizing viral capsids4,9.
In this study, we tested other organic compounds such as
glycerol, glucose, maltose and rafﬁnose in the same concentration
range and with approximately the same viscosity at RT. Weak
stabilization was often observed at lower concentrations, but at
higher concentration the effect was smaller or in some cases
destabilizing (representative data sets for different saccharides
and glycerol at different concentrations after storage of Ad5 for
5 days at 37 C are shown for sucrose on VSV in Supplementary
Figs 1C and 2). We usually observed that di- and tri-saccharides
usually stabilize the virus capsid better than monosaccharides.
However, we observed that glycerol is clearly destabilizing
(Ad5 and VSV).
Taken together, our results show that neither a general
stabilizing effect against protein unfolding nor an increase in
medium viscosity, both of which are common to many sugars,
is sufﬁcient to explain the enhancement of adenovirus lifetime
due to sucrose. In the Supplementary Discussion section, we
explore one possible alternative in the context of our model of
mechanical adenovirus degradation: if the loss of infectivity
happens via spontaneous rupture of the capsid due to thermal
ﬂuctuations and the mechanical stresses exerted by the conﬁned
genome, it could be mitigated by an enhancement of capsid
protein–protein-binding strengths due to sucrose. A crude model
of this process shows that a small increase of 1% in the binding
strength of the capsid protein–protein interactions would
be sufﬁcient to explain the marked stabilization of Ad5 at
both temperatures (Supplementary Discussion section). Since
sucrose is known to enhance protein–protein binding at molar
concentrations by modifying protein hydration properties26, our
hypothetical mechanism provides an interesting avenue for future
studies. However, we stress that spontaneous rupture of the
capsid is just one possible degradation mechanism that is
consistent with the observed trends.
Next, we focused on ﬁnding additives that may be effective at
lower concentrations. Motivated by the possibility of protein
hydration playing a role in stability, we studied the effect of
high-molecular-weight polyethylene glycol (PEG), which is
known to affect protein–protein interactions by changing their
hydration32. Covalent binding of PEG was used in previous
studies by other researchers to prevent recognition by inhibiting
Ad5 antibodies33, as well as stabilize the virus under harsh
conditions34. One approach to increase the stability was the
genetic engineering of viral vectors or chemical modiﬁcation such
as crosslinking of capsid proteins35–37. These approaches include
also the interaction with nanomaterials and organic polymeric
structures35 as well as a predictive model36.
The effect of PEG8000 on adenovirus infectivity versus storage
time at various PEG concentrations is shown in Fig. 2. In
addition, the lifetime at 37 C versus the concentration was
calculated (Supplementary Fig. 3). Surprisingly, we observed
stabilization both at RT and at 37 C even at micromolar
concentrations (far lower than the concentration needed for virus
precipitation32). At RT, no measurable loss of infectivity was
observed in our assay for PEG concentrations above 10 6M. At
37 C, the lifetime reached a plateau at 10 days (Supplementary
Fig. 4). Since the effect of PEG on physical properties such
as protein solubility38, osmotic pressure39 and viscosity40 is
negligible at these low bulk concentrations, it is likely that the
capsid attracts PEG molecules via van der Waals forces to locally
enhance the PEG concentration in its vicinity. Such a local
enhancement, together with the exponential dependence of the
lifetime on the activation energy DE (equation (2)), could explain
the large stabilization effect at small PEG concentrations as long
as the local PEG concentration is high enough to affect DE. DLS
data indicate that PEG increases the thermal stability of the viral
capsid at increasing temperatures up to 40 C (Supplementary
Fig. 1 (yellow line)).
PEG might be the ideal solution for the challenge of viral
vaccine stabilization, as it is a Food and Drug Administration-
approved polymer. Unfortunately, it does generate production of
anti-PEG antibodies or hypersensitivity in up to 50% of people
exposed to PEG41.
Finally, we tested the effect of electrostatic interactions
between the virus and NPs of similar size to PEG (whose
radius of gyration is 3.5 nm (ref. 42)) but with a high surface
charge density imparted by charged ligands43. Anionic gold NPs
with core diameter of 2.8±0.7 nm (transmission electron
microscopy (TEM) images and particle size distribution
are reported in Supplementary Fig. 4) were coated with
11-mercaptoundecansulphonate (MUS) and octanethiol (OT) in
a 4:1 stoichiometric ratio as measured by 1H-nuclear magnetic
resonance, bearing a zeta potential of  35mV. These NPs were
mixed with the virus in the concentration range of 1 10 8 to
2 10 6M (Supplementary for details on molar concentration
calculations for these NPs). Virus stability was measured for up to
28 days at RT and at 37 C (Fig. 3a–c). A gradual but signiﬁcant
increase in virus lifetime with NP concentration was observed,
up to 12 days at RT and saturating at 2.5 days at 37 C.
As with PEG, the bulk properties of the solution were
practically unchanged at the small values of NP concentration,
suggesting a local enhancement of NP concentration near the
virus capsid.
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In contrast to PEG, however, the enhancement of additive
concentration near the virus could be independently veriﬁed
in the case of NPs. DLS and cryo-TEM measurements
(Supplementary Fig. 5) of Ad5 in the presence of NPs support
the formation of a cloud of NPs around virus particles as a
potential reason for the stabilization of the virus capsid. These
observations imply an attractive interaction between Ad5 and
NPs. At the colloidal scale, the prominent interactions are van
der Waals and screened Coulomb interactions. We estimate
the effective pair potential between a NP and a virus particle
from these two contributions, as discussed in detail in the
Supplementary Discussion section. The NP and virus are both
assumed to be uniform spheres. Although the electrostatic
component of the interaction is highly repulsive, the van der
Waals forces are sufﬁcient to promote an attraction of  1.3 kBT
at around 3 nm separation. The low binding strength, by itself, is
not sufﬁcient to promote a thermodynamically stable complex of
NPs bound to the virus particle. However, Ad5 has a
non-uniform distribution of charged domains on its surface,
which includes regions that are locally electropositive even
though the net surface charge of the virus is negative. The
binding energy is expected to be lower (that is, stronger) than
 1.3 kBT in these domains, providing a possible mechanism for
a thermally stable local enhancement of MUS:OT NP concentra-
tion near the virus surface (Supplementary Figs 5 and 6).
A cloud of highly charged macroions changes the capsid
environment in two ways. On one hand, the enhanced
concentration of neutralizing counter ions applies an osmotic
pressure on the capsid due to the Donnan effect44. On the
other hand, the accompanying negative electrostatic potential
makes exposure of the negatively charged DNA energetically
unfavourable45. Changing the sign of the macroion charge does
not affect the ﬁrst effect but drastically changes the second,
by making DNA exposure more favourable and potentially
enhancing virus degradation. To help elucidate the mechanism
for virus stabilization due to NPs, we repeated our measurements
with cationic NPs of similar size, but coated with N,N,
N-trimethyl(11-mercaptoundecyl) ammonium chloride and OT
in 1:1 ratio resulting in a zeta potential of þ 60mV. These
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positively charged NPs have a core diameter of 4.9±1.1 nm
(TEM images and particle size distribution in Supplementary
Fig. 7). At a concentration of 10 7M, the cationic NPs show a
strong destabilizing effect, reducing the lifetime of virus particles
from days to minutes (Fig. 3d). In this case, both, the van der
Waals and electrostatic contributions are attractive, indicating a
high propensity for NPs to bind to the virus (Supplementary
Fig. 8). This observation is consistent with the electrostatic
interactions, rather than osmotic pressure changes, being the
main determinant of virus stability in the presence of highly
charged NPs. We expect anionic NPs to induce a stabilizing effect
regardless of their constituents.
To test the generality of this approach, we measured the
stabilization of Ad5 at RT and at 37 C for a number of other
anionic gold NPs. These other tested particles varied in size
(20 nm citrate gold NPs) or ligand shell composition (ranging
from particles coated solely with MUS to NPs coated with
mixtures of 3-mercapto-1-propane sulphonic acid and OT). As
shown in Supplementary Fig. 9 all tested negatively charged NPs
show a stabilization of the viral infectivity at day 5 and 37 C.
As a ﬁrst step to establishing the feasibility of our approach for
real vaccines, we introduce some initial in vivo studies with an Ad
expressing the NSP1 (Ad-NSP1) from Chikungunya virus. NSP1
is highly targeted by T cells in mice, monkeys and humans, and is
a potential vaccine target46,47. Because NSP1 is a cytoplasmic
protein, the Ad-NSP1 does not elicit neutralizing antibody
responses but induces a robust T-cell response. This potential
vaccine is being tested in preclinical trials because it elicits a very
robust T-cell response by 10 days post vaccination. This vaccine
approach is in line with using Ad vector in general as a delivery
system for chimeric vaccines (for example, currently ongoing
clinical trials for Ad-based Ebola vaccines). Determining whether
stabilization of the Ad-NSP1 vaccine enhances immunogenicity
after long-term storage will indicate the feasibility and
translatability of the additive-based approach to vaccines.
To determine the impact of long-term stabilization on Ad
vector immunogenicity, we incubated Ad-NSP1 either in PBS,
0.6M sucrose, 0.9mgml 1 of the anionic MUS:OT NPs or
10 6M PEG8000 for 10 days at RT or at 37 C. At the end of the
incubation period, aliquots of virus from each condition were
titred by limiting dilution on 293iq cells. The sucrose solution
preserved Ad-NSP1 infectivity 42.1-fold over PBS alone at RT
(2.8 107 versus 1.3 107 plaque-forming units (p.f.u.) per ml),
and stabilized the virus 43.4-fold over PBS alone at 37 C
(2.0 106 versus 5.8 105 p.f.u. per ml). The PEG solution
preserved Ad-NSP1 infectivity 10-fold over PBS at RT (1.3 108
versus 1.3 107 p.f.u. per ml and 448-fold at 37 C compared
with PBS (2.8 107 versus 5.8 105 p.f.u. per ml)
(Supplementary Fig. 10). To determine whether this increase in
vector stabilization by sucrose, MUS:OT NPs and PEG impacts
the immunogenicity of Ad vectors, mice were vaccinated
with 100 ml of the stabilized viruses by intramuscular injection.
At 11 days post vaccination, mice were killed and lymphocytes
were prepared from the spleen of each animal (n¼ 5). Interferon-
gamma ELISpot analysis of the splenocytes was used to quantify
the frequency of T cells responding to the vaccine (Fig. 4 and
Supplementary Fig. 9). Splenocytes were incubated for 2 days in
the presence of a NSP1 peptide pool, dimethylsulphoxide
(negative control) or phorbol myristate acetate/ionomycin
(positive control).
All of the mice had a similar background level of activated T
cells (cells treated with dimethylsulphoxide) and similar response
to the positive control (phorbol myristate acetate/ionomycin)
indicating that stabilization of the Ad vectors had no effect on
general T-cell responses in the mice. However, mice vaccinated
with Ad-NSP1 stabilized in sucrose had signiﬁcantly increased
frequency of NSP1-speciﬁc T cells compared with mice
vaccinated with Ad in PBS. This effect was more pronounced
for virus stabilized in sucrose at 37 C compared with RT (T-cell
frequency was increased 412 versus 2-fold (Fig. 4)). These data
indicate that stabilization with sucrose, at either temperature,
markedly increased the functional immunogenicity of Ad-NSP1.
It also indicates that there is a threshold of Ad required to elicit
T-cell responses and that sucrose stabilization promotes retention
of this activity compared with PBS alone. Mice vaccinated with
Ad-NSP1 stabilized in PEG at RT had a signiﬁcant increase in
T-cell responses against NSP1 compared with mice vaccinated
with Ad-NSP1 stored in PBS. However, mice vaccinated with
Ad-NSP1 stabilized in PEG at 37 C had very similar T-cell
responses to mice vaccinated with the Ad-NSP1 stabilized in PBS
at 37 C (Fig. 4). Our in vivo results show that we could obtain
immunogenicity in mice injected with viral vectors kept at 37 C
for 10 days. These data indicate that Ad stabilization by PEG
increased immunogenicity at RT; however, the immunogenicity is
diminished when the Ad is stabilized in PEG at 37 C, despite
retention of infectivity indicating that there are additional
requirements that are met by stabilization with sucrose but not
PEG. Importantly, these results indicate that when our additives
show large effects in vitro, we observed also a preservation of
the in vivo immunogenicity of the viral vaccine. The exception
are anionic NPs. If they are used for Ad virus stabilization,
no difference was found compared with the PBS stored virus
despite the good in vitro stabilization for the Ad-GFP.
Discussion
Our study presents simple solutions to the cold chain problem for
vaccines, extending the lifetime of virus particles by days and even
months at RT and at elevated temperatures. Sugars have the
advantages of being inexpensive and have shown the best
performance but only at high concentrations. NPs and polyols
are more expensive, but show effects at extremely small
concentrations. The rate of infectivity loss is characteristic of a
degradation mechanism with a single rate-limiting step. This
opens up the development of quantitative models of viral
degradation mechanisms, a simple but illustrative example of
which has been presented in the Supplementary Discussion
section. Given the high costs for the development of vaccine
formulations, we expect that our results will have an impact
especially for the new generations of chimeric vaccines that are
currently under development. Moreover, this study could be a
starting point to develop more solutions for the stabilization of
viral particles, depending on the speciﬁc medical need of virus-
based applications (that is, vaccines, therapies and viral gene
delivery systems).
Data availability. The data sets generated during and/or analysed
during the current study are available from the corresponding
authors on reasonable request.
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